EFTR vs. AMPE, CALA, ONCSQ, ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, and BFRIW
Should you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.
eFFECTOR Therapeutics vs.
Ampio Pharmaceuticals (NYSE:AMPE) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.
In the previous week, Ampio Pharmaceuticals and Ampio Pharmaceuticals both had 1 articles in the media. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.
5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
eFFECTOR Therapeutics has a consensus target price of $24.00, indicating a potential upside of 11,999,900.00%. Given eFFECTOR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe eFFECTOR Therapeutics is more favorable than Ampio Pharmaceuticals.
eFFECTOR Therapeutics received 23 more outperform votes than Ampio Pharmaceuticals when rated by MarketBeat users. Likewise, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 0.00% of users gave Ampio Pharmaceuticals an outperform vote.
Ampio Pharmaceuticals has a beta of 3.71, indicating that its share price is 271% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
Ampio Pharmaceuticals has higher earnings, but lower revenue than eFFECTOR Therapeutics. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
eFFECTOR Therapeutics beats Ampio Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
Get eFFECTOR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
eFFECTOR Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:EFTR) was last updated on 1/21/2025 by MarketBeat.com Staff
Free EFTR Stock Alerts